PROCEPT BioRobotics (PRCT) The 44th Annual William Blair Growth Stock Conference summary

Market overview and clinical need

• BPH affects 40 million men in the U.S., with prevalence rising as the population ages.

• 12 million men are actively managed for BPH, but many avoid treatment due to side effects and limited efficacy of current options.

• Resective procedures offer better efficacy but higher risks, while non-resective options are safer but less durable.

• Practices need a range of technologies to address varying prostate sizes and shapes.

• Aquablation aims to address all prostate sizes with improved safety and efficacy.

Technology and clinical data

• Aquablation uses image-guided robotic surgery, providing precise resection and sparing of tissue.

• Clinical trials showed similar or better efficacy and safety compared to TURP, especially in larger prostates.

• Studies validated consistent procedure times and efficiency, supporting practice workflow.

• 95%+ of target patients have access, with strong Medicare and commercial coverage.

• High surgeon retention and Net Promoter Scores support adoption.

Commercial strategy and expansion

• Focused on high-volume hospitals initially, now expanding to low and mid-volume hospitals with similar adoption rates.

• 30% of systems now placed in low and mid-volume hospitals, enabling more local procedures.

• International sales account for about 10% of revenue, with early traction in the U.K. and Japan.

• U.S. remains the primary growth driver, but disciplined international expansion is underway.